Boule

1956 The first European cell counter developed by Erik Öhlin.

1969 Swelab Instrument AB founded by Erik Öhlin.

1982 Medonic AB founded by Ingemar Berndtsson and Bram Bottema.

1990 Karo Bio Diagnostics AB founded as a diagnostic research company.

1992 New owners of Karo Bio Diagnostics and company renamed to Boule.

1994 Boule Nordic AB, life science distribution, established as wholly owned subsidiary.

1996 Boule Diagnostics International AB set up as holding company.

1997 Swelab Instrument AB acquired.

1998 Medonic AB and Bio Trend AB acquired. ISO-certification of Boule.

1999 Boule Medical AB formed by merger of Swelab and Medonic focusing on instruments for hematology analysis.

2001 Private placement to support aggressive development with focus on hematology for human and veterinary markets.

2002 Joint venture with Clinical Diagnostics Solutions (CDS) is established.  CDS develops, produces and markets reagents, and blood controls for diagnosis in hematology and chemistry.

2003 Company decision to establish pilot factory in Sweden.

2004 Receive 510(k) approval for Medonic CA 620. Boule acquires Clinical Diagnostics Solutions (CDS).

2005 Boule Nordic AB merged with Labdesign AB to form Nordic Biolabs AB. Boule owns 50% of the new subsidiary. Boule closes down the microbiology division in Huddinge which is rebuilt as Bactus AB. The wholly owned production facility, Boule Medical (Beijing) Co. Ltd, is established for efficient production and to strengthen Boule’s position in the Asian market. Boule embarks on a joint venture with Cholestech Inc (Alere) to develop an FDA registered hematology system with CLIA waived status for near patient testing, point-of-care.

2006 Launch of new generation of instruments with a common platform for Medonic and Swelab instruments.  This receives a positive market reaction.

2007 Point-of-Care system is an important milestone in the ability to demonstrate and verify POC functionality. A complete package of consumables (reagents, blood controls and calibrators) is developed for all instrument models. CDS receives ISO-certification which means that all subsidiaries within the company have ISO 9001 and/or ISO 13485 certificates.

2008 The first working POC prototype is tested. Direct sales in Poland established.

2009 The Medonic M-series system receives FDA 510(K) approval for marketing in the US.

2010 Launch of Quintus 5-part system. Direct sales operation start in Switzerland.  All 3-part instrument models can be produced in China.

2011 Exigo EOS is launched.